DLC-1 is an independent prognostic marker and potential therapeutic target in hepatocellular cancer.

The 5-year survival rate of patients with hepatocellular cancer (HCC) was very low because of invasion and metastasis in the early stage. Biomarkers might help predict early occurrence of invasion and metastasis. Accumulating evidence has shown that deleted in liver cancer-1 (DLC1) may be considered as a metastasis suppressor gene in numerous solid and hematological cancers. However, its prognostic role and mechanisms that regulate and coordinate these activities remain poorly understood.

With the method of immunohistochemistry, the expression of DLC-1 as well as Rho A, ROCK2, moesin had been characterized in 80 HCC tissues and adjacent noncancerous tissues. The correlation between their expression and their relationships with clinicopathological characteristics of HCC were also investigated. In addition, the prognostic value of DLC1 expression within the tumor tissues was assessed by Cox regression and Kaplan-Meier analysis.

DLC1 expression was significantly lower in HCC tissues than in adjacent noncancerous tissues, and DLC-1 expression was found to be negatively correlated with tumor differentiation, TNM stage and lymph node metastasis. Furthermore, DLC-1 expression was found to inversely correlate with Rho A, ROCK2 and moesin which were all highly expressed in HCC tissues. Kaplan-Meier analysis showed that significantly longer 5-year survival rate was seen in HCC patients with higher DLC1 expression, compared to those with lower expression of DLC1. Multivariate Cox proportional hazard analyses revealed that DLC1 was an independent factor affecting the overall survival probability.

DLC1 could be served as a tumor suppressor gene in the progression especially in the invasion and metastasis of HCC. DLC1 perhaps played its role by regulating the expression of Rho A, ROCK2 and moesin. Evaluation of the expression of DLC-1 might be a good prognostic marker for patients with HCC.

Diagnostic pathology. 2016 Feb 04*** epublish ***

L J Song, Q Liu, X R Meng, Sh L Li, L X Wang, Q X Fan, X Y Xuan

Department of Oncology, the first affiliated hospital of Zhengzhou University, Henan, 450000, China. This email address is being protected from spambots. You need JavaScript enabled to view it.., Department of Neurosurgery, the fifth affiliated hospital of Zhengzhou University, Henan, 450000, China. This email address is being protected from spambots. You need JavaScript enabled to view it.., Department of Oncology, the first affiliated hospital of Zhengzhou University, Henan, 450000, China. This email address is being protected from spambots. You need JavaScript enabled to view it.., Department of Pathology, the first affiliated hospital of Zhengzhou University, Henan, 450000, China. This email address is being protected from spambots. You need JavaScript enabled to view it.., Department of Oncology, the first affiliated hospital of Zhengzhou University, Henan, 450000, China. This email address is being protected from spambots. You need JavaScript enabled to view it.., Department of Oncology, the first affiliated hospital of Zhengzhou University, Henan, 450000, China. This email address is being protected from spambots. You need JavaScript enabled to view it.., Department of Microbiology and Immunology, Basic Medical School of Zhengzhou University, 100 Kexue Road, Zhengzhou, Henan, 450001, China. This email address is being protected from spambots. You need JavaScript enabled to view it..